Empagliflozin Favorably Reshaped LVs in HFrEF Patients Empagliflozin Favorably Reshaped LVs in HFrEF Patients
Treatment with the SGLT2 inhibitor empagliflozin led to significant reductions in both left ventricular end systolic and diastolic volumes in two independent randomized studies of patients with heart failure with reduced ejection fraction.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
More News: Cardiology | Empagliflozin | Heart | Heart Failure | Jardiance | SGLT2 Inhibitors | Study